Trial document

This trial has been registered retrospectively.
drksid header


Trial Description

start of 1:1-Block title


Safety and protective efficacy of a simplified Plasmodium falciparum sporozoite chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Malaria vaccine study: Live malaria pathogens are administered to healthy volunteers for immunisation, whereby the parasites are simultaneously attenuated by a malaria drug (chloroquine). After the first immunization (day 0), this is repeated 5 and 28 days later. The number of pathogens is controlled by the administration of medication, so that only weak malaria symptoms can be expected or even avoided.
The success of this vaccination is tested by re-administration of the malaria pathogens, but without simultaneous administration of the malaria drug. If immunisation was successful, the subjects should not develop any symptoms (except for the control group). This so-called "challenge" is performed three times in total, 10, 26 and 52 weeks after the last immunization.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

A new regime of a malaria vaccine shall be tested, which is based on the administration of living Plasmodium falciparum sporozoites (PfSPZ, strain NF54), specially prepared for human use, and the simultaneous administration of the malaria drug chloroquine (resoquin) in healthy, voluntary, malaria-naïve volunteers.
The vaccination schedule envisages the administration of chemoprophylaxis and PfSPZ shortly after, on days 0, 5 and 28.
The vaccination success is tested 10 weeks after the last immunisation by administering a heterologous strain of PfSPZ, with no simultaneous chemoprophylaxis. The longevity of the vaccine protection is tested again using the same method 26 and 52 weeks after the last immunization.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00017462
  •   2019/06/21
  •   [---]*
  •   yes
  •   Approved
  •   919/2018AMG1, Ethik-Kommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2018-004523-36 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Malaria vaccine study
  •   B50 -  Plasmodium falciparum malaria
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Aseptic, purified, vialed, cryopreserved, fully infectious Plasmodium falciparum Sporocoites:
    110.000 PfSPZ (strain NF54, Sanaria Inc), under Chloroquin chemorporhylaxis (10 mg/kg/day) on days 0,5,28.

    3.200 PfSPZ (strain 7G8, Sanaria Inc) 10, 26 and 52 Wochen past day 28.

  •   Isotonic saline solution (0.9 % NaCl), 0.5 ml per injection on days 0, 5, 28.

    3.200 PfSPZ (strain 7G8, Sanaria Inc) 10, 26 and 52 Wochen past day 28.
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, investigator/therapist
  •   Placebo
  •   Prevention
  •   Parallel
  •   I
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Safety: at least possibly related Grade 3-4 Adverse Events;

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Efficacy: proportion of protected volunteers, with protection defined as parasites absent from peripheral blood in a 28 days follow-up period after PfSPZ administration without chemoprophylaxis.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2019/05/02
  •   21
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   45   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Consent to all study procedures, healthy adults with BMI < 35, who are living in Tübingen or the surrounding area, in women: active contraception.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

History of P. falciparum, previous intake of a malaria vaccine, intake of other investigational products in the past 90 days, HIV, HepB or HepC positive, intake of medications that affect the immune system, recent or present pregnancy or breastfeeding, retinal or metabolic disease, blood count abnormalities, allergy to drugs to be used, serious chronic conditions, seizure or cancer, or risk of heart attack, or Cardiac arrhythmias in the medical history, abnormal ECG, 3 or more vaccinations in the last 4 weeks

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • DZIF - Deutsches Zentrum für Infektionsforschung
    • Inhoffenstraße 7
    • 38124  Braunschweig
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.